- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Transcript
How do you think payers are going to manage having so many adalimumab biosimilars to choose from?
Casberg: That's what we do as a company: we help people make formulary and drug management decisions. So, I see there's 3 options. As a payer, you can stay with AbbVie’s [product] all the way, which avoids member disruption and makes things more smooth but you don't get biosimilar adoption. And from an optics perspective, I think adoption of biosimilars is becoming more required these days.
So, one option is AbbVie, all in. You may not get quite as much savings as going with biosimilars, but you also now don’t have some of the hurdles and hassles you get with going with biosimilars.
Number 2 is going middle of the road. Keep Humira [reference adalimumab] on formulary, but also add some biosimilars at parity. So, have both options available. It allows you to maintain some Humira rebate and also allows you to take advantage of some biosimilars savings. So that's option 2, kind of meeting halfway.
And then the last one is biosimilars, all in. Take [Humira] off formulary and go all in with biosimilars. Try to convert as much of the market share as you can.
So, those are the strategies, and as far as all those different options you probably add the [originator], and/or 1 or 2 of the biosimilars, and then see how the cards fall.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
